Conditional approval for Hansa’s kidney transplant drug
Idefirix is an immunosuppressant that reduces the level of donor specific antibodies, thus enabling transplantation
Read More
Tag: Idefirix
Eight medicines leap towards EU approval
The recommendations include a conditional approval for Gilead’s Veklury (remdesivir) for COVID-19
Read More
EMA accepts marketing authorisation applications for Idefirix and Xospata
European regulators have accepted for review marketing authorisation applications for Hansa’s Idefirix and Astellas’ Xospata.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
